课题基金 / 基金详情

UAB CF Research and Translation Core Center

UAB CF Research and Translation Core Center
UAB CF 研究与翻译核心中心
批准号:
10673353
负责人:
David M. Bedwell
金额:
$111.38万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
未结题
起止时间:
2007-04-01 至 2028-04-30
关键词:
AccelerationAchievementAddressAnimal ModelAnimalsAreaBacterial InfectionsBasic ScienceBiological AssayBiological ModelsBiomedical ResearchCell LineCell modelCellsCellular AssayChronicClinicalClinical SciencesClinical TrialsCollaborationsCollectionCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDedicationsDiseaseDrug IndustryEducationEducational workshopElementsEnvironmentErythrocytesEvaluationExhibitsFacultyFeasibility StudiesFerretsFosteringFoundationsFunctional disorderFundingFutureGenerationsGeneticGoalsGrowthHemolysisHumanImageInfectionInflammationInstitutionInterdisciplinary CommunicationInterdisciplinary StudyInternationalInvestigationInvestigational TherapiesKetonesKnowledgeLaboratoriesLeadershipLungLung diseasesMeasuresMentorshipMutationNational Institute of Diabetes and Digestive and Kidney DiseasesNonsense MutationOrganoidsOutcome MeasureOutputPathogenesisPatientsPhysiologicalPilot ProjectsPopulationPositioning AttributePre-Clinical ModelPredispositionRattusReagentResearchResearch PersonnelResearch PriorityResearch SupportResourcesRoleSamplingScienceScientific Advances and AccomplishmentsSenior ScientistSeriesServicesSiteStructureSupplementationSystemTechniquesTestingTherapeuticTherapeutic InterventionTrainingTranslatingTranslational ResearchTranslationsTreatment ProtocolsUnited StatesUnited States National Institutes of HealthUniversitiesVX-770Workage relatedbasecareer developmentclinical centerclinical translationcollaborative environmentcystic fibrosis patientsdesigndrug discoveryeffectiveness researchexperiencegene therapyimprovedin vivoinnovationinventionmembermodel developmentmultidisciplinarynext generationnovelnovel therapeuticspreventprogramsrepositoryrespiratoryresponsesuccesssynergismtherapeutic evaluationtherapy developmenttooltool developmenttraining opportunitytranslational scientisttranslational therapeuticsworking group

项目摘要

项目成果

David M. Bedwell的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT The UAB P30 Research and Translation Core Center consolidates a large number of externally funded cystic fibrosis (CF) research programs on our campus, building an innovative environment to pursue, advance, and train in CF-related science. During the last funding period, the P30 made robust and important contributions to multiple UAB laboratories of our Research Base of over 70 investigators pursuing research relevant to CFTR modulation; CF pathogenesis; novel outcome measures for the genetic therapy era; infection and inflammation in the context of highly effective modulator therapy; and therapeutic translation for untreated CFTR mutations. By virtue of the NIH Center, translational research at our Institution has continued to accelerate in the past five years, as has the breadth of investigators. The richness of CF basic science at UAB has grown in parallel with this translational expansion, providing numerous opportunities to exploit in the next funding period, and the Center is strategically structured to take advantage of these opportunities. The P30 Center has allowed investigators at UAB and collaborating sites to improve understanding of CF disease mechanism and has furnished novel opportunities to aggressively apply this information towards experimental therapeutics, including genetic-based therapies that will continue to grow in emphasis. This NIH Center includes three Biomedical Research Cores that help to organize efforts of CF faculty towards the common and essential goal of helping individuals with CF and to train the next generation of CF leaders. The Cores include: Core A: Cell Model and Assay Core (GM Solomon and J Guimbellot, Co-PIs); Core B: Animal Models Core (DM Bedwell and S Birket, Co-PIs); and Core C: Clinical and Translational Core (SM Rowe and A Gaggar, Co-PIs). Each Core provides leading-edge assays, specialized reagents and techniques, and valued expertise. The P30 has also engaged new investigators through a Pilot and Feasibility mechanism integral to Center vitality and has a tight integration with the UAB Center for Clinical and Translational Science, enabling a robust training environment. In addition to providing a platform from which junior and senior scientists are brought into the field, Pilot Projects serve as a means of rapidly testing exciting advances, particularly from the perspective of clinical translation. Two Pilot and Feasibility Projects are in progress: Project 1: R Patel, PI. “Erythrocyte Hemolysis and Lung Disease in CF”; and Project 2: E Plaisance, PI. “Ketone Monoester Supplementation in CF: A Pilot and Feasibility Study”, capitalizing on the next era of innovative opportunities to transform the disease. Through these scientific initiatives, the P30 has added value to a collaborative environment for CF research at our Institution, and is well-positioned to continue in this capacity in the future, with a major focus on therapeutic translation.
期刊论文(380)
专著(0)
科研奖励(0)
会议论文
DOI: 10.3390/nu14061216
发表时间: 2022-03-13
期刊: Nutrients
影响因子: 5.9
作者: [Bailey J, Krick S, Fontaine KR]
通讯作者: Fontaine KR
DOI: 10.1056/nejmoa0909825
发表时间: 2010-11-18
期刊: The New England journal of medicine
影响因子: --
作者: [Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW]
通讯作者: Ramsey BW
DOI: 10.3390/nu14050933
发表时间: 2022-02-22
期刊: Nutrients
影响因子: 5.9
作者: [Nicolson WB, Bailey J, Alotaibi NZ, Krick S, Lowman JD]
通讯作者: Lowman JD
DOI: 10.1038/s41525-020-00154-9
发表时间: 2020
期刊: NPJ genomic medicine
影响因子: 5.3
作者: [Marshall CR, Chowdhury S, Taft RJ, Lebo MS, Buchan JG, Harrison SM, Rowsey R, Klee EW, Liu P, Worthey EA, Jobanputra V, Dimmock D, Kearney HM, Bick D, Kulkarni S, Taylor SL, Belmont JW, Stavropoulos DJ, Lennon NJ, Medical Genome Initiative]
通讯作者: Medical Genome Initiative
212
    New Nonsense Suppression Drugs to Treat MPS I
    Mechanism of Eukaryotic Translation Termination
    Suppression of the Idua-W402X mutation in an MPS I-H mouse
    UAB CFRC Administrative Core
    海外基金